The application of EZH2 inhibitors improved lupus-like symptoms in MRL/lpr mice, lowered the production of type I interferon in NZW/NZB F1 mice and reduced GC formation and autoantibody secretion in bm12 induced lupus-like cGVHD. Here, EZH2 is linked to systemic lupus erythematosus.